Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benmelstobart
- Development stage
- Phase 4
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Benmelstobart (TQB2450) is a humanized IgG1 monoclonal antibody that targets programmed death-ligand 1 (PD-L1). It acts as an immune checkpoint inhibitor by blocking the interaction between PD-L1 and its receptors, PD-1 and B7.1, thereby restoring T-cell mediated antitumor immune responses. Developed by Chia Tai Tianqing Pharmaceutical Group, benmelstobart is being investigated across a broad range of solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), esophageal squamous cell carcinoma (ESCC), triple-negative breast cancer (TNBC), and endometrial cancer. It is frequently evaluated in combination with anlotinib, a multi-targeted tyrosine kinase inhibitor, to enhance therapeutic efficacy through synergistic modulation of the tumor microenvironment and immune response.
- Brand names
- benmelstobart
- Other names
- TQB2450TQB-2450TQB 2450
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on benmelstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benmelstobart.